You just read:

Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

News provided by

Theravance Biopharma, Inc.

Sep 19, 2017, 08:30 ET